SCHEMBL392365

SCHEMBL392365

CC[C@@H](C(=O)O)C(O)CC#N

nearest known ligand 0.34

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.33
CHRM1 P11229 1/20 0.33
AKR1A1 P14550 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
DRD3 P35462 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
OR51E2 Q9H255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL197703 1.00 TDP1 (0.33) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL395419 1.00 TDP1 (0.33) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL198107 1.00 TDP1 (0.33) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL6239351 0.84 CHRM1 (0.40) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL6240565 0.81 CA2 (0.41) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL3837519 0.77 TDP1 (0.42) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL687714 0.77 TDP1 (0.42) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL6234803 0.75 CTSS (0.34)
SCHEMBL16667373 0.74 TP53 (0.38) OR51E2
SCHEMBL1406003 0.74 TP53 (0.38) OR51E2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208259-A1 Halohydrin Dehalogenases and Related Polynucleotides CODEXIS, INC. (US) 2012-08-16 US claimed
EP-1727795-B1 PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM RANBAXY LAB LTD (IN) 2012-02-15 EP claimed
US-7932064-B2 Converting epichlorohydrin to 3-hydroxyglutaronitrile, catalyzing the conversion of the 3-hydroxyglutaronitrile to 4-cyano-3-hydroxybutyric acid by contacting with polypeptide having a nitrilase activity; intermediate for atorvastatin VERENIUM CORPORATION (US) 2011-04-26 US claimed
US-7521216-B2 Nitrilases and methods for making and using them VERENIUM CORPORATION (US) 2009-04-21 US claimed
EP-2874992-B1 PROCESS FOR CROSSED CLAISEN CONDENSATION REACTIONS PROMOTED BY LITHIUM AMIDE IN LIQUID AMMONIA BAKHU LTD (GB) 2020-04-15 EP disclosed
US-20150197476-A1 PROCESS FOR CROSSED CLAISEN CONDENSATION REACTIONS PROMOTED BY LITHIUM AMIDE IN LIQUID AMMONIA BAKHU PHARMA LTD (GB) 2015-07-16 US disclosed
EP-2874992-A1 PROCESS FOR CROSSED CLAISEN CONDENSATION REACTIONS PROMOTED BY LITHIUM AMIDE IN LIQUID AMMONIA Bakhu Pharma Limited (GB) 2015-05-27 EP disclosed
CN-104357468-A Parvibaculum lavamentivorans ZJB 14001, halohydrin dehalogenase enzyme gene, enzyme, engineered bacterium and application UNIV ZHEJIANG TECHNOLOGY 2015-02-18 CN disclosed
US-20140051869-A1 CONTINUOUS PROCESS FOR THE PRODUCTION OF BETA-KETO ESTERS BY CLAISEN CONDENSATION PHOENIX CHEMICALS LIMITED (GB) 2014-02-20 US disclosed
WO-2014013261-A1 PROCESS FOR CROSSED CLAISEN CONDENSATION REACTIONS PROMOTED BY LITHIUM AMIDE IN LIQUID AMMONIA BAKHU PHARMA LIMITED (GB) 2014-01-23 WO disclosed
US-8535910-B2 Halohydrin dehalogenases and related polynucleotides CODEXIS, INC. (US) 2013-09-17 US disclosed
US-20130130333-A1 Processes for Making (R)-Ethyl 4-Cyano-3 Hydroxybutyric Acid VERENIUM CORPORATION (US) 2013-05-23 US disclosed
US-20040137585-A1 Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives CODEXIS, INC. 2004-07-15 US disclosed
WO-2004027075-A2 CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STAIN INTERMEDIATES DIVERSA CORPORATION (US) 2004-04-01 WO disclosed
US-20040053378-A1 Processes for making (R)-ethyl 4-cyano-3-hydroxybutyric acid DIVERSA CORPORATION (US) 2004-03-18 US disclosed
WO-2004015132-A2 ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES CODEXIS, INC. (US) 2004-02-19 WO disclosed
WO-2003106415-A2 PROCESSES FOR MAKING (R)-ETHYL 4-CYANO-3-HYDROXYBUTYRIC ACID DIVERSA CORPORATION (US) 2003-12-24 WO disclosed
WO-2003097581-A1 CONTINUOUS PROCESS FOR THE CYANATION OF HYDROGENATED BETA-KETOESTERS PHOENIX CHEMICALS LIMITED (GB) 2003-11-27 WO disclosed
US-6603015-B2 Antitumor agents; anticancer agents; malaria; Alzheimer's disease UNIVERSITY OF KANSAS 2003-08-05 US disclosed
US-20020156289-A1 Synthesis of epothilones THE UNIVERSITY OF KANSAS 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051869-A1 CONTINUOUS PROCESS FOR THE PRODUCTION OF BETA-KETO ESTERS BY CLAISEN CONDENSATION AKR1C4, AKR1C3, AKR1C2 TDP1 4555/4885CHRM1 1989/4885AKR1A1 8/4885
US-20150197476-A1 PROCESS FOR CROSSED CLAISEN CONDENSATION REACTIONS PROMOTED BY LITHIUM AMIDE IN LIQUID AMMONIA BCAT1, ELOVL3, COASY TDP1 4523/4885CHRM1 3735/4885AKR1A1 749/4885
US-20020156289-A1 Synthesis of epothilones ADH1C, ADH1A, ADH5 TDP1 4423/4885CHRM1 1564/4885AKR1A1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.